Objective: Interferon-alpha (IFNalpha) levels are elevated in many patients with systemic lupus erythematosus (SLE) and may play a primary role in its pathogenesis. The purpose of this study was to determine whether serum IFNalpha activity in SLE patients and their healthy first-degree relatives is highest in early adulthood, when the incidence of SLE is greatest.
Methods: Serum samples from 315 SLE patients, 359 healthy first-degree relatives, and 141 healthy unrelated donors were measured for IFNalpha activity using a functional reporter cell assay. IFNalpha activity was analyzed in relation to age, and subgroups with high levels of IFNalpha activity were identified within the large data sets using a Mann-Whitney sliding window segmentation algorithm. The significance of each subgrouping was ranked by Kruskal-Wallis testing.
Results: Age was inversely correlated with IFNalpha activity in female SLE patients (r = -0.20, P = 0.001) as well as their healthy female first-degree relatives (r = -0.16, P = 0.02). In male patients and their healthy male first-degree relatives, there was no significant overall correlation between age and serum IFNalpha activity. The segmentation algorithm revealed significantly increased IFNalpha activity between the ages of 12 and 22 years in female SLE patients and between the ages of 16 and 29 years in male SLE patients. Both male and female healthy first-degree relatives had significantly decreased IFNalpha activity after the age of 50 years.
Conclusion: Serum IFNalpha activity is higher in younger individuals in the SLE family cohorts, and this tendency is accentuated in affected individuals. This age-related pattern of IFNalpha activity may contribute to the increased incidence of SLE in early adulthood, and interestingly, males and females had similar age-related patterns of IFNalpha activity.
Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients.Arthritis Rheum. 2008 Aug;58(8):2481-7. doi: 10.1002/art.23613. Arthritis Rheum. 2008. PMID: 18668568 Free PMC article.
Large-scale analysis of tumor necrosis factor α levels in systemic lupus erythematosus.Arthritis Rheum. 2012 Sep;64(9):2947-52. doi: 10.1002/art.34483. Arthritis Rheum. 2012. PMID: 22488302 Free PMC article.
Network analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosus.Arthritis Rheum. 2011 Apr;63(4):1044-53. doi: 10.1002/art.30187. Arthritis Rheum. 2011. PMID: 21162028 Free PMC article.
Interferon-alpha in systemic lupus erythematosus.Curr Opin Rheumatol. 2004 Sep;16(5):541-7. doi: 10.1097/01.bor.0000135453.70424.1b. Curr Opin Rheumatol. 2004. PMID: 15314491 Review.
Anti-interferon alpha treatment in SLE.Clin Immunol. 2013 Sep;148(3):303-12. doi: 10.1016/j.clim.2013.02.013. Epub 2013 Mar 1. Clin Immunol. 2013. PMID: 23566912 Review.
Cited by 44 articles
Type I Interferon Predicts an Alternate Immune System Phenotype in Systemic Lupus Erythematosus.ACR Open Rheumatol. 2019 Aug 19;1(8):499-506. doi: 10.1002/acr2.11073. eCollection 2019 Oct. ACR Open Rheumatol. 2019. PMID: 31777831 Free PMC article.
Interferon pathway in SLE: one key to unlocking the mystery of the disease.Lupus Sci Med. 2019 Aug 13;6(1):e000270. doi: 10.1136/lupus-2018-000270. eCollection 2019. Lupus Sci Med. 2019. PMID: 31497305 Free PMC article. Review.
Conventional DCs from Male and Female Lupus-Prone B6.NZM Sle1/Sle2/Sle3 Mice Express an IFN Signature and Have a Higher Immunometabolism That Are Enhanced by Estrogen.J Immunol Res. 2018 Apr 15;2018:1601079. doi: 10.1155/2018/1601079. eCollection 2018. J Immunol Res. 2018. PMID: 29850618 Free PMC article.
Associations between type I interferon and antiphospholipid antibody status differ between ancestral backgrounds.Lupus Sci Med. 2018 Jan 13;5(1):e000246. doi: 10.1136/lupus-2017-000246. eCollection 2018. Lupus Sci Med. 2018. PMID: 29387437 Free PMC article.
Enhanced IFN-α production is associated with increased TLR7 retention in the lysosomes of palasmacytoid dendritic cells in systemic lupus erythematosus.Arthritis Res Ther. 2017 Oct 19;19(1):234. doi: 10.1186/s13075-017-1441-7. Arthritis Res Ther. 2017. PMID: 29052537 Free PMC article.
- R01 DE015223/DE/NIDCR NIH HHS/United States
- N01AR62277/AR/NIAMS NIH HHS/United States
- R01 DE015223-05/DE/NIDCR NIH HHS/United States
- AR-62277/AR/NIAMS NIH HHS/United States
- P20 RR020143/RR/NCRR NIH HHS/United States
- P50 AR048940-010001/AR/NIAMS NIH HHS/United States
- R01-AI-059893/AI/NIAID NIH HHS/United States
- AI-31584/AI/NIAID NIH HHS/United States
- AR-49084/AR/NIAMS NIH HHS/United States
- R01 AI031584-13/AI/NIAID NIH HHS/United States
- R21 AI053747-02/AI/NIAID NIH HHS/United States
- T32-AR-07517/AR/NIAMS NIH HHS/United States
- P30 AR053483/AR/NIAMS NIH HHS/United States
- R01 AI031584/AI/NIAID NIH HHS/United States
- DE-15223/DE/NIDCR NIH HHS/United States
- R01 AI059893-04/AI/NIAID NIH HHS/United States
- AI62629/AI/NIAID NIH HHS/United States
- AR-42460/AR/NIAMS NIH HHS/United States
- R01 AI024717-16/AI/NIAID NIH HHS/United States
- N01 AR062277/AR/NIAMS NIH HHS/United States
- AI-24717/AI/NIAID NIH HHS/United States
- AR-48940/AR/NIAMS NIH HHS/United States
- AI-071651/AI/NIAID NIH HHS/United States
- T32 AR007517/AR/NIAMS NIH HHS/United States
- U19 AI062629/AI/NIAID NIH HHS/United States
- R37 AI024717/AI/NIAID NIH HHS/United States
- R01 AR042460/AR/NIAMS NIH HHS/United States
- R01 AI059893/AI/NIAID NIH HHS/United States
- R01 AI024717/AI/NIAID NIH HHS/United States
- L30 AI071651/AI/NIAID NIH HHS/United States
- AI-53747/AI/NIAID NIH HHS/United States
- U19 AI062629-010006/AI/NIAID NIH HHS/United States
- P50 AR048940/AR/NIAMS NIH HHS/United States
- RR-20143/RR/NCRR NIH HHS/United States
- L30 AI071651-01/AI/NIAID NIH HHS/United States
- R21 AI053747/AI/NIAID NIH HHS/United States
- P01 AR049084/AR/NIAMS NIH HHS/United States
- R01 AR042460-15/AR/NIAMS NIH HHS/United States
- P20 RR020143-05/RR/NCRR NIH HHS/United States
- P01 AR049084-010002/AR/NIAMS NIH HHS/United States